European journal of clinical pharmacology
-
Eur. J. Clin. Pharmacol. · Aug 2003
Randomized Controlled Trial Clinical TrialPharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.
The aim of this study was to evaluate the effect of acetylsalicylic acid (ASA or aspirin) on the pharmacokinetics (PK) and pharmacodynamics (PD) of melagatran in healthy volunteers. Melagatran is the active form of the oral direct thrombin inhibitor, ximelagatran. ⋯ In young healthy volunteers, ASA had no effect on the PK or PD properties of melagatran at the studied dose. That the combination of ximelagatran with ASA may be used with acceptable safety must be verified in the relevant patient populations.
-
Eur. J. Clin. Pharmacol. · Aug 2003
Historical ArticlePlacebo effect and placebos: what are we talking about? Some conceptual and historical considerations.
Placebos and the placebo effect have always been present in medical history. However, they have not received the same consideration over the years. ⋯ Knowledge of the conceptual and historical considerations of placebo may help to understand its role in medical practice. Even without a consensual definition, and assuming that the placebo effect does not seem to be fully dependent on a placebo administration, one issue seems unquestionable: the placebo effect is present in clinical practice and in clinical trials, no matter which name we choose to call it.